Edmund A. Rossi

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

David M. Goldenberg, Thomas M. Cardillo, Serengulam V. Govindan et al. · Oncotarget · 2015 · 447 citations · Full text

A Novel Method of ¹⁸F Radiolabeling for PET

William J. McBride, Robert M. Sharkey, Habibe Karacay et al. · Journal of Nuclear Medicine · 2009 · 400 citations · Full text

Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers

Thomas M. Cardillo, Serengulam V. Govindan, Robert M. Sharkey et al. · Bioconjugate Chemistry · 2015 · 280 citations

Anti-trop-2/sn-38 Antibody–drug Conjugate, Immunology, Immunoediting +20

Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting

Edmund A. Rossi, David M. Goldenberg, Thomas M. Cardillo et al. · Proceedings of the National Academy of Sciences · 2006 · 210 citations · Full text

Engineering, Lock Method, Defined Composition +20

An Intramembrane Modulator of the ErbB2 Receptor Tyrosine Kinase That Potentiates Neuregulin Signaling

Kermit L. Carraway, Edmund A. Rossi, Masanobu Komatsu et al. · Journal of Biological Chemistry · 1999 · 197 citations · Full text

Tumor Biology, Signaling Pathway, Receptor Tyrosine Kinase +17